View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Generic Drug Development: 505(j) ANDAs and Potential Diversification

PDG and its staff have participated in more than 100 505(j) abbreviated new drug applications (ANDA) submissions.

NDA and ANDA approvals

PDG and its staff have participated in more than 100 505(j) abbreviated new drug applications (ANDA) submissions.

PDG is well-versed in the requirements for safety and bioequivalence studies (and when applicable, bio-waivers); labelling; chemistry, manufacturing, and controls (CMC); and the potential of patent challenges.

PDG will orchestrate ANDA drug candidate selections, compilation and submission of the application including patent and RLD considerations, maintenance activities and interactions with the US Food and Drug Administration (FDA).

Support for diversification and generic drug development

Whether you are a foreign firm contemplating your first US generic development project, or an established US generic firm seeking to undertake a 505(b)(2) development programme, PDG supports generic manufacturers in the diversification of their development programmes to include commercially reasonable 505(j), 505(b)(1) and 505(b)(2) NDA opportunities.

PDG also has extensive experience with pharmaceutical labelling of new drug applications (NDA), ANDAs, and supplements. The FDA recently announced critically important information for all generic drug manufacturers, which may require generic drug manufacturers to develop and implement safety-related changes to their labelling.

If implemented, generic companies will have a paradigmatic shift in their role related to safety surveillance and labelling updates. PDG is uniquely positioned to assist with any new FDA post-marketing requirements, safety assessments, and pharmacovigilance efforts to help ensure the continued adequacy of professional labelling.

Clinical trial consulting and pharmaceutical consulting professionals will benefit by becoming current on adaptive trial design.
Safety surveillance and pharmacovigilance consulting to generic drug manufacturers, as well as generic drug labelling consulting may soon become a service in demand.
Pharmaceutical Development Group (PDG) is a drug and medical device consultant that continuously engages in meetings and interactions with the US Food and Drug Administration...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology